

KURZPROTOKOLL
CP-MGAH22-06

| | |
|--|---|
| Öffentlicher Titel | Phase II/III Studie zu Margetuximab bei HER2-positivem Krebs des Magens oder Magenübergangs |
| Wissenschaftl. Titel | Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer |
| Kurztitel | CP-MGAH22-06 |
| Studienart | multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, mehrarmig |
| Studienphase | Phase II/III |
| Erkrankung | Verdauung: Magen-/Speiseröhrenkrebs (Magen-/Ösophaguskarzinom): neoadjuvant |
| Einschlusskriterien | <ul style="list-style-type: none">- Histologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2+ GC or GEJ adenocarcinoma Prior systemic perioperative treatment is allowed; however the patient must have had a disease-free interval of at least 6 months from end of chemo/surgery Patients receiving perioperative anti-HER2 therapy require testing of HER2 status for eligibility Cohort A: HER2-positive (by IHC 3+) and PD-L1-positive (by IHC with 22C3 CPS \geq 1%) per central review Cohort B: HER2-positive (by IHC 3+ or IHC 2+ in combination with FISH+) by local review. PD -L1 status is not required for enrollment- Availability of formalin-fixed, paraffin-embedded tumor specimen, unstained slides or contemporaneous biopsy for tumor target testing- Eastern Cooperative Oncology Group performance status of 0 or 1, verified within 3 days of Day 1- Life expectancy \geq 6 months- At least one radiographically measurable target lesion- Acceptable laboratory parameters and adequate organ function |
| Ausschlusskriterien | <ul style="list-style-type: none">- Other malignancy that is progressing or required treatment within the past 5 years, with certain exceptions Patients with known MSI-H status- History of allogeneic stem cell or tissue/solid organ transplant- Central nervous system metastases- Clinically significant cardiovascular disease, gastrointestinal disorders, pulmonary compromise Prior neoadjuvant or adjuvant treatment with immunotherapy |
| Alter | 18 Jahre und älter |
| Molekularer Marker | HER2/neu pos. |
| Prüfzentren | Krankenhaus Nordwest GmbH (Geschlossen) Institut für klinisch-onkologische Forschung Steinbacher Hohl 2-26 60488 Frankfurt am Main Prof. Dr. med. Salah-Eddin Al-Batran Tel: 069 7601 4420 albatran@khnw.de |
| Sponsor | MacroGenics |
| Registrierung in anderen Studienregistern | ClinicalTrials.gov NCT04082364 (primäres Register) EudraCT 2019-004699-21 |